{"id":"W4406158969","doi":"10.1080/17474086.2025.2450223","title":"Characterizing the ideal patient for treatment with inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: a systematic literature review","year":2025,"lang":"en","type":"review","venue":"Expert Review of Hematology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Occupational Cancer Research Centre; Cancer Care Ontario","funders":"Pfizer","keywords":"Medicine; Refractory (planetary science); Lymphoblastic Leukemia; Gemtuzumab ozogamicin; Oncology; Intensive care medicine; Leukemia; Internal medicine; Pediatrics; Stem cell","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0009381174,0.001455477,0.01384422,0.0004265876,0.0002049351,0.00003354461,0.0007987013,0.000739805,0.00003329929],"category_scores_gemma":[0.002283327,0.0006836978,0.002483068,0.001007474,0.0002644468,0.0001008554,0.0002099537,0.0004739333,0.00002405714],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.004449772,"about_ca_system_score_gemma":0.007811624,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001052478,"about_ca_topic_score_gemma":0.000002602118,"domain_scores_codex":[0.9924788,0.0009202436,0.00367864,0.001231006,0.0007062787,0.0009849883],"domain_scores_gemma":[0.987891,0.006069895,0.002642561,0.002228474,0.0009158794,0.0002522151],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0001907024,0.0001758408,8.447313e-8,0.8699745,0.002432634,0.0002160501,0.0001680469,1.024869e-8,0.00000273958,0.0003396479,0.01866742,0.1078323],"study_design_scores_gemma":[0.001365003,0.001798426,1.851814e-8,0.5349409,0.008953049,0.004960545,0.00001655752,0.000009569164,0.0000106657,0.000002955037,0.4476633,0.0002790166],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[6.055258e-7,0.9614971,0.0006132813,0.001120346,0.0004143191,0.03573651,0.0004242342,0.00006934828,0.000124289],"genre_scores_gemma":[0.000001206959,0.9609779,0.001813187,0.004472914,0.0002020183,0.03028356,0.001490769,0.0001819627,0.0005764618],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.4289959,"threshold_uncertainty_score":0.9998195,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02011902196243325,"score_gpt":0.3459785393528343,"score_spread":0.3258595173904011,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}